Study: Vaporized, Low-Potency Cannabis Mitigates Neuropathic Pain http://norml.org/news/2013/01/03/study-vaporized-low-potency-cannabis-mitigates-neuropathic-pain Thursday, 03 January 2013 Davis, CA: The administration of vaporized, low THC cannabis is associated with reduced pain in subjects with neuropathy, according to clinical trial data published online by The Journal of Pain. Investigators at the University of California, Davis Medical Center conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in 39 subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Subjects inhaled cannabis of either moderate THC (3.53 percent), low dose THC (1.29 percent), or zero THC (placebo). Subjects continued to take all other concurrent medications as per their normal routine during the 3- to 4-week study period. Spontaneous pain relief, the primary outcome variable, was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain). Researchers reported: "Both the low and medium doses proved to be salutary analgesics for the heterogeneous collection of neuropathic pain conditions studied. Both active study medications provided statistically significant 30% reductions in pain intensity when compared to placebo." They concluded: "Both the 1.29% and 3.53% vaporized THC study medications produced equal antinociception at every time point. ... [T]he use of low doses could potentially be prescribed by physicians interested in helping patients use cannabis effectively while minimizing cognitive and psychological side effects. Viewed with this in mind, the present study adds to a growing body of literature supporting the use of cannabis for the treatment of neuropathic pain. It provides additional evidence of the efficacy of vaporized cannabis as well as establishes low-dose cannabis (1.29%) as having a favorable risk-benefit ratio." Previous clinical trials have indicated that inhaled cannabis can safely and effectively relieve neuropathy, a hard-to-treat nerve condition often associated with cancer, HIV, spinal cord injury, diabetes, multiple sclerosis, and other conditions. Separate trial data further indicates that inhaled "cannabis augments the analgesic effect of opioids" and therefore "may allow for opioid treatment at lower doses with fewer side effects." For more information, please contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, "Low-dose vaporized cannabis significantly improves neuropathic pain," appears in The Journal of Pain.